Eli Lilly highlights ACR data; is the stock still 8% undervalued?
FROM THE WIRE · FINANCE.YAHOO.COM
Eli Lilly (LLY) just used the American College of Rheumatology Convergence 2026 meeting to spotlight fresh data on retatrutide, Zepbound and Taltz in obesity linked to joint and autoimmune disease. Eli Lilly sits at a share price of US$1,364.73 after a recent pullback of about…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishNew clinical data and raised guidance support the stock, which is down on the day.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Lilly presented data on retatrutide, Zepbound and Taltz at the ACR Convergence 2026 meeting.
- 02The stock trades at $1,364.73 after a pullback of about 3.8% on the day.
- 03Year-to-date gain is 26.3%, following strong third-quarter results.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets